You are here: Home » 2022 » Archives for May 2022

Late-breaking Results Show Efficacy for CCM in Patients With HFpEF

MADRID and MARLTON, N.J., May 23, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a late–breaking presentation of results from the CCM–HFpEF Piloty Study, which is the largest clinical trial to date studying the effects of the company's proprietary CCM therapy to treat HF with preserved ejection fraction (HFpEF). The results presented "" including a substantial 18 point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life score "" indicate that, for patients with heart failure and left ventricular ejection fraction (LVEF) 50%, CCM therapy not only offered meaningful improvement in quality of life but also substantially decreased hospitalizations versus the patient's experience prior to the Optimizer implant. The results were presented at the European Society of Cardiology's Heart Failure 2022 Congress.

Patients with HFpEF suffer from debilitating symptoms and have very few therapeutic options. This patient population is a similar size as the one with reduced ejection fraction and has been shown to have similar struggles with quality of life, hospitalizations, and mortality.

Cecilia Linde, MD, Professor and Consultant in Cardiology at the Heart and Vascular Theme of Karolinska University Hospital and the Karolinska Institute in Stockholm, Sweden, who was the co–principal investigator for this investigation, said, "The CCM–HFpEF Pilot Study was conducted to explore the hypothesis that CCM therapy might benefit patients with HFpEF. Our hypothesis was based on evidence of greater benefits in CCM HFrEF studies in those with higher LVEF range and from case reports of HFpEF patients. In our CCM–HFpEF–Pilot Study, we found significant benefits from CCM therapy in patients with preserved LVEF, supporting prior findings. I look forward to following the progress of the recently begun pivotal AIM HIGHer trial to continue this journey further."

Dr. Ishu Rao, Medical Director for Impulse Dynamics, welcomed these results because they confirm the potential for positive results in the company's recently initiated AIM HIGHer trial. "We are also excited to announce that enrollment is well underway for this landmark IDE–approved, multicenter, randomized, and blinded pivotal trial designed not only to confirm Dr. Linde's groundbreaking work presented today but to go further yet by providing the first long term morbidity and mortality results for a modern Optimizer CCM device. While Dr. Linde specifically studied patients with EFs 50%, in AIM HIGHer, we are examining the efficacy of CCM therapy in 1,500 patients with EFs between 40% and 60%. This represents a large cohort of patients who currently have minimal treatment options and are clamoring for help. If AIM HIGHer's results are consistent with Dr. Linde's findings, we may finally begin to close the significant gap in care that exists for millions of patients afflicted with HF and higher EF."

HF affects more than 64 million people worldwide and leads to dramatic declines in a patient's quality of life. Patients are often classified by a measure of cardiac function known as the ejection fraction (EF), which describes the percentage of blood pumped out of the left ventricle with each heartbeat. CCM therapy is currently indicated in Europe for patients that have an EF below 50% and has been proven to reduce hospitalizations. However, HF patients with higher EF have had few therapeutic options thus far to alleviate their symptoms and treat their disease.

The purpose of the AIM HIGHer trial "" the largest randomized, sham–controlled, device–based interventional heart failure trial "" is to further assess the potential of CCM to improve performance and reduce cardiovascular morbidity and mortality for these patients. CCM therapy for HFpEF has already received the FDA's breakthrough device designation. The Breakthrough Devices Program is a voluntary program for certain medical devices that provide more effective treatment or diagnosis of life–threatening or irreversibly debilitating diseases or conditions. The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review while preserving the statutory standards consistent with the Agency's mission to protect and promote public health.

The Optimizer Smart Mini delivers CCM therapy which consists of precisely timed electrical pulses sent to the heart. These signals are designed to improve the heart's ability to function properly, allowing more oxygen–rich blood to be pushed out through the body.

About Impulse Dynamics

Impulse Dynamics, based in Marlton, NJ, is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company has pioneered CCM therapy, which is delivered by the company's Optimizer Smart Mini, an FDA–approved treatment verified to improve the quality of life for certain heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.

Forward–looking Statements

This press release contains forward–looking statements. All statements other than statements of historical facts contained in this press release are forward–looking statements. In some cases, you can identify forward–looking statements by terms such as ""may,'' ""will,'' ""should,'' ""expect,'' ""plan,'' ""anticipate,'' ""could,'' ""intend,'' ""target,'' ""project,'' ""contemplate,'' ""believe,'' ""estimate,'' ""predict,'' ""potential'' or ""continue'' or the negative of these terms or other similar expressions, although not all forward–looking statements contain these words. Forward–looking statements include, but are not limited to, statements concerning: potential benefits of CCM therapy and the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short–term and long–term benefits of the Optimizer Smart Mini and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward–looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward–looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the Company's future research and development costs, capital requirements and the Company's needs for additional financing; commercial success and market acceptance of CCM therapy; the Company's ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer Smart and Optimizer Smart Mini systems or any future products the Company may seek to commercialize; competitive companies and technologies in the industry; the Company's ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the Company's business model and strategic plans for its products, technologies and business, including its implementation thereof; the Company's ability to expand, manage and maintain its direct sales and marketing organization; the Company's ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the Company's ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The Company does not undertake any obligation to update forward–looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward–looking statements contained herein. These forward–looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

###


GLOBENEWSWIRE (Distribution ID 8557987)

DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES PARTNERSHIP WITH AGA KHAN UNIVERSITY TO LAUNCH FIRST ALZHEIMER’S RESEARCH INITIATIVE IN EAST AFRICA

GENEVA, SWITZERLAND, May 23, 2022 (GLOBE NEWSWIRE) —

  • Research Will Produce Digital Cognitive Assessments and Collect Blood Samples for Gene Sequencing Models
  • Clinical Trial Will Conduct Late–Stage Potential Treatment for Alzheimer's
  • Builds on AKU's Brain and Mind Institute to Develop Integrated Brain Health Frameworks

The Davos Alzheimer's Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer's disease, today announced a partnership with the Brain & Mind Institute at Aga Khan University (AKU) in Kenya, East Africa to launch a two–part research program for Alzheimer's: a cohort research study, and a clinical trial. Both will address the longstanding lack of diversity in Alzheimer's research, aim to improve care, and increase access to future innovative treatments throughout Africa.

To date, nearly all studies of Alzheimer's disease have been conducted on white populations of Western European origin, meaning that 90 percent of the world's population has been left out.[1] The Davos Alzheimer's Collaborative is responding to this lack of diversity by building a cohort of one million people, to date, 30 cohorts from 23 countries within North America, South America, Europe, Asia, and with this new partnership with the Brain & Mind Institute (BMI), AKU, Africa.

The partnership with the BMI/AKU is a trailblazing collaboration to fundamentally rethink Alzheimer's data collection and analysis. Because the research will be open source, it will help scientists and researchers worldwide gain a better understanding of Alzheimer's in vulnerable and underserved populations; which in turn, can accelerate the development of new treatments reflecting a precision medicine approach.

"To make progress on Alzheimer's Disease, it is essential that research include all races and ethnicities, especially diverse populations who have been left out of previous research efforts," said George Vradenburg, Founding Chairman of the Board, Davos Alzheimer's Collaborative, and Convener, The Global CEO Initiative on Alzheimer's Disease. "This partnership with the Brain and Mind Institute/Aga Khan University will build knowledge across racial, ethnic, gender, and national boundaries which will lay the foundation for new breakthroughs."

DAC and BMI will use local networks and on–the–ground healthcare providers to collect blood and conduct digital cognitive assessments, which are critical to identifying biomarkers that may indicate the presence of Alzheimer's disease.

"We are excited to partner on this cutting–edge study to broaden our understanding of Alzheimer's disease in Sub–Saharan Africa," said Zul Merali, Founding Director of the Brain and Mind Institute, AKU. "This work comes at a critical time as the entire continent of Africa is grappling with issues of healthy aging and ill health, particularly pertaining to dementia and Alzheimer's disease."

DAC is transforming research in Alzheimer's, working with researchers to make sure they have tools and technology to gather data, then pooling this information so the global scientific community can understand the heterogeneity of Alzheimer's disease. The DAC/AKU partnership will play a key role in shaping a future of accessible, globally competent Alzheimer's treatment.

About the Davos Alzheimer's Collaborative

Launched at the World Economic Forum's 2021 meeting on The Davos Agenda, The Davos Alzheimer's Collaborative is a multi–stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer's presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer's Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.

About the Brain and Mind Institute, AKU

The Brain and Mind Institute (BMI) at the Aga Khan University, operates in East Africa and Central/South Asia. BMI's ethos is to span from neuron to the neighborhood, and across multi–country campuses. The operational model is to empower and strengthen neuroscience and mental health research and interventions through capacity building and partnerships; connecting the rich tapestry of academics, research entities, stakeholders, and communities of lived experience. BMI facilitates interdisciplinary research, education and innovation in mental health and neurosciences. Through transdisciplinary research approaches, BMI aims to impact the lives of people who are affected by debilitating neurological and mental health problems. Whether it is uncovering the causes of illness or advancing breakthrough research into treatments or interventions, BMI's approach is always mindful of the local needs of the people and communities at risk.

[1] https://www.davosalzheimerscollaborative.org/cohorts


GLOBENEWSWIRE (Distribution ID 8557970)

DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES EARLY DETECTION INNOVATION GRANTS

GENEVA, SWITZERLAND, May 23, 2022 (GLOBE NEWSWIRE) — The Davos Alzheimer's Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer's disease, today announced the recipients of a grant program aiming for early detection of cognitive symptoms. The early detection grants total $4.5 Million from 8 countries across North America, Europe, Asia, and Africa.

The grants are an initiative of the DAC Healthcare System Preparedness Project, which aims to advance how healthcare systems worldwide detect, diagnose, treat, and care for people with or at risk for Alzheimer's.

Grantees are located throughout the US, Brunei, Kenya, Germany, Japan, Canada, Cuba, and Armenia. Several grants will focus on expanding cognition screening and training for primary care providers. Others are harnessing innovative technologies to utilize optometrists and pharmacists. This will expand the pool of frontline workers available to screen for early detection, and reduce the unnecessary use of specialist care. Another deploys a mobile clinic to offer direct clinical support or equip digital tablets to volunteer workers to rapidly improve detection rates.

According to George Vradenburg, Founding Chairman of the Board, Davos Alzheimer's Collaborative, "Each grant will bring unique and measurable benefits to its local health system and community and, through DAC's global learning network, will also spread their learnings broadly around the world. Finding new and innovative ways to advance early detection is paramount to improving healthcare systems' abilities to provide better care today, and to prepare for the future availability of treatments."

The grant application process was extensive, with DAC receiving 76 responses from 21 countries in two months. A diverse panel of experts, including a family member of an Alzheimer's patient living with the disease, served as an independent review committee for these grants:

  • Tarun Dua (Global) "" World Health Organization
  • Wendy Weidner (Global) "" Alzheimer's Disease International
  • Ricardo Allegri (Argentina) "" University of Buenos Aires & World Dementia Council
  • Chirine Chehab (Lebanon) "" American University Hospital of Beirut
  • Lori Frank (United States) "" RAND Corporation & New York Academy of Medicines
  • Ryoji Noritake (Japan) "" Health and Global Policy Institute
  • Terry Fulmer (United States) "" John A. Hartford Foundation
  • Chandresh Harjivan (Canada) "" Family member of an Alzheimer's patient

"Early detection of cognitive decline is critical for patients and families and I am excited to see the Davos Alzheimer's Collaborative tackling this challenge with their Health System Preparedness Initiative," says Chandresh Harjivan, a family member of an Alzheimer's patient. "I was honored to be asked to be part of such an esteemed review committee and am very happy that families living with the disease were part of the evaluation process."

A summary of each grant can be found below.

About the Davos Alzheimer's Collaborative

Launched at the World Economic Forum's 2021 meeting on The Davos Agenda, The Davos Alzheimer's Collaborative is a multi–stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer's presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer's Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.

About DAC's Healthcare System Preparedness Project

DAC's Healthcare System Preparedness Project (DAC–SP) is funding innovative approaches that measurably increase rates of cognitive screening, early detection and accurate diagnosis of Alzheimer's through pilot projects and early detection grants. The pilot projects are: AdventHealth Central Florida, FL, USA; Municipality of Volta Redonda, State of Rio de Janeiro, Brazil; Alzheimer Scotland; University of the West Indies (UWI), Caribbean Institute for Health Research, Jamaica; Kobe University, Japan; INGER/National Institute of Geriatrics, Mexico; and, Indiana University School of Medicine/Indiana University Health, IN, USA. These initiatives are incorporated into DAC Learning Labs, a network of governments and public health and healthcare system leaders, to share best practices that can be scaled globally.

###

***PLEASE NOTE: Click here to view a recorded discussion with some of the grant recipients, in which over 500 global leaders from 53 countries tuned in to learn about early detection. Click here to be kept informed about updated information regarding the DAC initiative.

Davos Alzheimer's Collaborative Early Detection Grants

Toronto Memory Program and RetiSpec (Canada)

This project implements the world's first screening model that leverages collaboration between optometry and a local Alzheimer Society chapter to enable accessible identification of individuals at risk for Alzheimer's disease and referral to a qualified clinician, facilitating a faster diagnosis. The two community–based entry points include: (1) optometry clinics, where individuals can receive a non–invasive RetiSpec retinal scan for early detection of Alzheimer's disease; and (2) the Alzheimer Society of Toronto, where individuals can undergo cognitive assessment.

Ludwig–Maximillans University (Germany)

Partners with two Universities, a health and social care charity, and three industry partners to conduct three screening types on seniors in Germany. This study will identify the best screening method by offering digital cognitive assessments, SCD questionnaire screening, and blood AD biomarkers testing to different groups. This study will also generate a patient registry to enroll patients in the global cohort and clinical trials workstreams, establish a fluid biobank, and train Artificial Intelligence diagnostic systems to better analyze speech patterns.

University of Havana (Cuba)

Provides a two–month training to primary care providers to integrate tablet based cognitive assessments Brain Health Assessment (BHA). The care provider will be assisted by informants, meaning a family–member or other person close to the patient, to help primary care providers determine if a dementia diagnosis is warranted.

Avant Institute (US – Multiple States)

This project implements Cognivue Clarity, a self–administered 10–minute cognitive performance screening tool, to increase access to digital cognitive screening assessments in 20–30 Community Pharmacy Enhanced Services Network (CPESN) pharmacy sites across rural, urban, and underserved communities throughout the United States. This project provides training and onboarding for pharmacies to use Cognivue to screen patients and evaluate the results to make further recommendations and referrals.

Africa Mental Health Research and Training Foundation (Kenya)

This project redeploys existing volunteer staff in the Strengthening Responses to Dementia in Developing Countries (STRiDE) project and trains community health workers to screen 2,400 people aged 60 and above. Workers are equipped with tablets to conduct the screening Instrument for Dementia (CSI–D) cognitive assessment and informant interview, word list recall task, and Euro–Dementia scale. Ultimately, results will inform health system policy and practices in Kenya.

Alzheimer's Care Armenia (Armenia)

This cognitive screening education programs utilizes a van that has been outfitted as a multidisciplinary mobile clinic to offer educational programs and work with local clinical staff to screen for cognitive issues using the Montreal Cognitive Assessment (MOCA). The program provides citizens who test positive for cognitive decline with healthcare resources and offers workshops to caregivers on providing support.

Advocate Aurora Health (US– Illinois)

This project aims to educate primary care providers on the importance of early cognitive screening and provide them with EPIC electronic health record–based digital testing tools to manage their patients efficiently. Clinicians get access to continuing education programming, eConsult support services, and participate in a monthly Project ECHO–type case conference to discuss topics on dementia.

Kobe City Pharmaceutical Association (Japan)

This project evaluates the value of pharmacy–based digital cognitive tests. It combines the cognitive test with a regular healthcare consultation to increase regular cognitive testing, the rate of early detection of cognitive decline, and timely and accurate diagnosis of dementia in local community–based healthcare system.

University of Washington (US– Washington)

This project expands the pilot site success of the Gerontological Society of America (GSA) Kickstart, Assess, Evaluate and Refer (KAER Toolkit, 2020 Edition) into a fully operational Cognition in Primary Care (CPC) protocol in seven new primary care clinics across the University of Washington. The CPC model includes provider education training and incorporates two validated tests, the Montreal Cognitive Assessment (MoCa) and the Ascertain Dementia 8–Item Informant Questionnaire (AD8), and a structured Cognitive Checklist. This model checks for comorbidities of dementia and provides guidance on follow–up counseling and referrals to community resources.

Demensia (Brunei)

This project will perform a pilot test of community screening and information in Senior Citizen Activity Centers, followed by a focus group discussion to select an initial paper–based cognitive assessment. The project will systematically involve communities at grassroots levels – senior citizen activity centres, engagement of village heads and community centres, targeting older people and those with dementia risk factors. Community links formed by the association are available for multisectoral support with this initiative. Other project activities also include training of field workers regarding community screening and cognitive assessment and training workshops for primary care (followed by relevant specialties).

American Academy of Physician Associates and Cleveland Clinic (US "" Ohio)

Through partnership with The American Academy of Physician Assistants (AAPA), the Physician Associate (PA) Foundation, and Cleveland Clinic, this project develops cognitive assessment toolkit for non–specialist medical practitioners to be trained in administering screenings, interpreting results, communicating those results and offering additional provider and patient resources. The pilot implementation will be followed by outcomes reporting and dissemination of the toolkit to the network of PA schools and all Cleveland Clinic locations.

Institute for Healthcare Improvement (IHI) (US – Massachusetts)

This project uses a systems redesign approach, working with approximately eight teams across a range of settings on testing and measuring the results of intervention strategies that increase assessment rates. IHI will build and operate a learning community to encourage peer learning among participating teams, provide guidance, and teach scientific improvement methods to facilitate the teams' testing. Project outputs include a prototype set of interventions, implementation guidance, and an associated measurement set that will be ready to share and scale more widely.


GLOBENEWSWIRE (Distribution ID 8557953)

Crocus Delivers the Future of High Precision, High Current Contactless Isolated Current Sense

MILPITAS, Calif., May 23, 2022 (GLOBE NEWSWIRE) — Crocus Technology Inc., the leading supplier of disruptive TMR (Tunnel Magneto–Resistance) XtremeSense sensors, today announced the CT45x family of contactless isolated current sensors to enable high precision and high current measurements in a more simplified solution. Unlike existing solutions, the CT45x allows manufacturers to eliminate costly shields, concentrators or cores. The CT452 and CT453 offers contactless 0.7% accuracy, 1 MHz bandwidth, and better than –50 dB immunity to external magnetic fields without additional mechanical components. This combination of performance and accuracy enables customers to reduce their overall product size and weight which enables them to replace large and costly current sense modules with a small and simple solution.

As current requirements have been increasing so have the challenges of accurately measuring high currents, typically >200 A and often up to 2,000 A. Shunt resistors with isolated amplifiers are broadly used but present an issue with I2R losses and tend to be large and costly. Existing magnetic based solutions like Hall Effect and AMR are less accurate and have high temperature drift. The CT45x products are based on XtremeSense TMR technology that delivers the future with a high signal–to–noise ratio (SNR) contactless approach which can scale with the system requirements, high bandwidth and fast response time, common–model field rejection, combined with high accuracy measurements over temperature.

In addition, many applications now require very accurate current measurements in the milliamp range up to the 1,000 A range or more. Often this type of solution involves multiple current sensors to achieve the desired system performance with many design compromises and complexities. Using Crocus' XtremeSense TMR current sensors allows for a no–compromise and simple solution using a single CT45x sensor which provides a large dynamic range and a high SNR. For example, the CT45x is able to measure down to 500 mA resolution and up to 1,800 A while maintaining better than 0.7% accuracy.

The CT45x offers groundbreaking noise performance, as low as 0.55 mVRMS, to enable applications to sense small current levels and small changes or variations in current through a busbar. This performance is almost 10 times better than existing Hall Effect solutions. This results in a SNR (signal–to–noise ratio) as high as 77 dB for the CT45x measurement which allows the system to process higher resolution data with higher accuracy.

"With the introduction of the CT45x family of contactless current sense products, we now have a complete portfolio of products for our customers from small currents to larger currents," states Zack Deiri, President and CEO of Crocus Technology. "This product based on Crocus' cutting–edge TMR technology is the most exciting for us as the benefits of our XtremeSense TMR are addressing the needs of higher current applications that can't be met with existing solutions without compromises. Crocus is excited to be addressing new high current markets such as BMS, Inverters, DC/DC Converter and many others."

Product features and performance:

CT450 & CT452 (5 V version) & CT453 (3.3 V version)

Isolated Contactless Current Sensor

Capable of measuring currents from 5 mA to >2,000 A

Total output error 0.7% Full–Scale

300 ns response time, 1 MHz bandwidth

Available in six different configured field ranges

Protection capability with Over Field Detection (OFD)

Integrated Common Mode Field Rejection (CMFR) with >90% immunity (CT452/3)

Uniform magnetic field sensing (CT450)

Targeting applications in EV Chargers, Battery Management Systems (BMS), DC/DC Converters, 48–V system, Bidirectional Charging and AC/DC Inverters.

The CT450 is available in TSSOP–8 package. The CT452/3 are available in TSSOP–16 package For more information, please visit the product webpage:

CT450 https://crocus–technology.com/products/ct450/

CT452 https://crocus–technology.com/products/ct452/

CT453 https://crocus–technology.com/products/ct453/

About Crocus Technology

Crocus Technology develops and manufactures state–of–the–art magnetic sensors based on its patented XtremeSense TMR sensor technology. Crocus' disruptive magnetic sensor technology enables the highest sensitivity, the lowest power consumption and smallest size over a wide temperature range. Crocus is headquartered in Milpitas, California. For more information, please visit http://www.crocus–technology.com.

For more information, please contact:

Crocus Technology
Email: info@crocus–technology.com


GLOBENEWSWIRE (Distribution ID 8547204)

Bombardier Introduces Global 8000 Aircraft, the Flagship for a New Era in Business Aviation

  • Bombardier's new Global 8000 aircraft stands alone as the world's fastest and longest–range purpose–built business jet, innovatively crafted with the industry's smoothest ride, healthiest cabin, and lowest cabin altitude
  • With its innovative Smooth Flex Wing and super–efficient Passport engines, the Global 8000 jet features a top speed of Mach 0.94 "" the fastest business jet in the skies
  • The Global 8000 aircraft will be the only true four–zone cabin business jet to have a range of 8,000 nautical miles, unlocking even more city pairs than ever before
  • Current Global 7500 operators will be able to retrofit their aircraft to experience the incredible performance enhancements on the Global 8000 aircraft

GENEVA, May 23, 2022 (GLOBE NEWSWIRE) — Bombardier today unveiled the newest member of its industry–leading business jet portfolio with the introduction of the Global 8000 aircraft, the world's fastest and longest–range purpose–built business jet, innovatively crafted with the industry's healthiest cabin for safety, comfort and performance beyond compromise.

With an industry–leading range of 8,000 nautical miles and an unbeatable top speed of Mach 0.94, the Global 8000 aircraft is the ultimate all–in–one business aircraft, offering customers a unique blend of outstanding performance married with the smoothest ride and an uncompromising passenger experience "" the absolute leader in the long–range class.

"Today, Bombardier solidifies once more its position as the leader in business aviation with the newest member of the industry–leading Global family," said ric Martel, Bombardier's President and Chief Executive Officer. "The Global 8000 aircraft leverages the outstanding attributes of the Global 7500 aircraft, providing our customers with a flagship aircraft of a new era. We remain unmatched, which for an innovation–focused team like us, is great."

Some of the impressive performance capabilities of the new Global 8000 aircraft were witnessed as early as May 2021, following a demonstration flight with a Global 7500 flight test vehicle. The aircraft, accompanied by a NASA F/A–18 chase plane, repeatably achieved speeds in excess of Mach 1.015, a key step in enabling a maximum Mach operating speed (MMO) of M0.94 and becoming the fastest business jet in the world and the fastest in civil aviation since the Concorde. During the demonstration flight, the aircraft also became the first Transport Category airplane to fly supersonic with sustainable aviation fuel (SAF).

The discerning Global 8000 business jet also features the healthiest cabin in the industry, with the lowest cabin altitude in its class of 2,900 feet when flying at 41,000 ft. It is also equipped with Bombardier's Pr Air and advanced HEPA filter technology for the cleanest cabin air and the fastest fresh air replacement.

The Global 8000 aircraft is the only true four–zone cabin business jet to have a range of 8,000 nautical miles "" and it more than delivers even when it comes to comfort. With its spacious four personalized suites ergonomically designed to maximize space and freedom of movement, the Global 8000 aircraft also incorporates the revolutionary features introduced on the Global 7500 aircraft that dramatically improve passenger comfort, including the Soleil circadian lighting system to help combat jet lag. Coupled with the innovative Nuage seat with the first–ever zero gravity position, passengers will arrive at their destinations revitalized and refreshed.

An exemplary commitment to detail is assured on the new Global 8000 aircraft, including an available Principal Suite with a full–size bed and a stand–up shower in the En–suite. Revolutionary cabin entertainment control and connectivity, the intuitive nice Touch CMS and OLED touch dial, Bombardier's l'Opra directional audio sound system and available 4K monitor, also ensures passengers will receive an unrivalled cabin experience.

In the cockpit, the Global 8000 aircraft features the renowned Bombardier Vision flight deck with its next generation fly–by–wire technology and blend of cutting–edge avionics with exceptional ergonomics and aesthetics for remarkable comfort and control.

Performance–wise, the new Global 8000 aircraft can efficiently transport customers to a wide variety of destinations both faster and farther than ever before. And with its exceptional class–leading range and short–field performance, even more exclusive city pairs are now achievable, including Dubai–Houston, Singapore–Los Angeles, London–Perth and many others.

Expected to enter service in 2025, the Global 8000 aircraft development is ongoing, and the program is progressing to plan. And for current Global 7500 operators, the incredible performance enhancements on the Global 8000 will be retrofittable when the aircraft enters into service in 2025.

The introduction of the new Global 8000 aircraft has been a carefully planned investment that further strengthens Bombardier's impressive portfolio of industry–defining business jets. Development to date has been included in previously disclosed investment figures. All further development costs will be included in Bombardier's capex, which remains in line with its 2025 objectives.

About Bombardier
Bombardier is a global leader in aviation, focused on designing, manufacturing, and servicing the world's most exceptional business jets. Bombardier's Challenger and Global aircraft families are renowned for their cutting–edge innovation, cabin design, performance, and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments, and private individuals. Bombardier aircraft are also trusted around the world in special–mission roles.

Headquartered in Montral, Qubec, Bombardier operates aerostructure, assembly and completion facilities in Canada, the United States and Mexico. The company's robust customer support network includes facilities in strategic locations in the United States and Canada, as well as in the United Kingdom, Germany, France, Switzerland, Italy, Austria, the UAE, Singapore, China, and an Australian facility opening in 2022.

For corporate news and information, including Bombardier's Environmental, Social and Governance report, visit bombardier.com. Learn more about Bombardier's industry–leading products and customer service network at businessaircraft.bombardier.com. Follow us on Twitter @Bombardier.

Bombardier, Bombardier Vision, Global, Global 7500 and Global 8000 are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

Visuals of the new Global 8000 aircraft are available here.

For information:
Matthew Nicholls
Bombardier
+1 514–243–8214
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/77b1c210–6034–4eed–b9a1–09fcf7298160


GLOBENEWSWIRE (Distribution ID 8557779)

Coinsfera launches an instant service to buy and sell Bitcoin (BTC) in Dubai

DUBAI, United Arab Emirates, May 20, 2022 (GLOBE NEWSWIRE) — The demand for buying and selling Bitcoin in Dubai increases at Coinsfera as the price of Bitcoin fluctuates. The most popular cryptocurrency Bitcoin experienced one of the significant dips.

The volatile cryptocurrency market has been on display during the previous several days. To avoid losing a substantial chunk of their cryptocurrency holdings, people hurried to sell and buy cryptocurrencies at various prices. While some preferred to sell Bitcoin in Dubai, others preferred to buy Bitcoin in Dubai at a lower price.

According to Coinsfera, due to the price fluctuations, thousands of people benefited from the services of Coinsfera in Dubai. Coinsfera allows them to convert cash to crypto, crypto to cash in Dubai, and help customers in the process. Given many customers join the crypto space each day, Coinsfera facilitates the process and within just a few minutes customers can buy and sell crypto in Dubai. As a result, customers benefited from instant Bitcoin to cash services in Dubai.

Coinsfera has allocated its resources to provide a seamless service experience for the crypto buyers and sellers in Dubai. The equipment and the professional staff enable Coinsfera to provide service on such a scale that all customers can easily buy and sell Bitcoin in Dubai. Besides Bitcoin, customers can buy and sell Ethereum (ETH), USDT (tether), and many other cryptocurrencies at Coinsfera.

Award–winning exchange enables to buy and sell Bitcoin in Dubai

Coinsfera has been nominated for multiple awards in the crypto space. One of the awards was received at the largest blockchain conference of MENA and the Eurasia regions. Coinsfera got this award at the Blockchain Economy Summit as a consequence of its active involvement.

As a reliable crypto shop, Coinsfera has operated as an OTC exchange since 2015, and service quality has been improved each year. Now it is even possible to buy and sell more than 2000+ cryptocurrencies at Coinsfera. Bitcoin (BTC), Binance Coin (BNB), Ripple (XRP), Cardano (ADA), and Polkadot (DOT) are some of the cryptocurrencies that are available at Coinsfera. Bitcoin remains the cryptocurrency with the most volume in the market and customers prefer to buy and sell BTC in Dubai.

About Coinsfera

Coinsfera is a cryptocurrency exchange that operates in Dubai – the UAE, Istanbul – Turkey, Pristina – Kosovo, and London– the UK. Coinsfera enables crypto enthusiasts to buy and sell Bitcoin, Ethereum, and many other cryptocurrencies within a few minutes. Besides those volatile cryptocurrencies, USDT, USDC, and other stablecoins can be bought at Coinsfera.

Sell Bitcoin in Dubai at Coinsfera
https://www.coinsfera.com/sell–bitcoin–in–dubai/

Buy Bitcoin in Dubai at Coinsfera
https://www.coinsfera.com/buy–bitcoin–in–dubai/

Sell crypto in Dubai at Coinsfera
https://www.coinsfera.com/sell–cryptocurrency–in–dubai/

Address: Jumeirah Lake Towers, Cluster F, Indigo–Icon tower – Office # 501 5th floor – Dubai – United Arab Emirates
Phone: +971 58 535 0505
Email: [email protected]
Website: https://www.coinsfera.com/


GLOBENEWSWIRE (Distribution ID 1000634660)

JETEX LONDON TO WOW PRIVATE JET FLYERS

Dubai, United Arab Emirates, May 20, 2022 (GLOBE NEWSWIRE) — London is a natural next destination for Jetex, an award–winning global leader in executive aviation, and it becomes the brand's 35th international FBO location. Jetex entered in an agreement with Avia Solutions Group to operate the FBO at Hangar 510 at Biggin Hill Airport (EGKB/BQH).

The airport rightfully holds a pride of place in British History. Opened in 1916, the property was vacated by the Royal Air Force in 1992 and has operated as a privately–owned civilian airfield dedicated to business and civilian aviation ever since.

Today, it is recognized as a global center of excellence and the second private jet operation in the UK with 23% of London's market share after Farnborough (31%) and ahead of Luton (22%). The airport typically connects flights to more than 750 destinations across over 70 countries, with over 90% of destinations being in Europe and 5% long haul.

Jetex London is conveniently located just 12 miles from Canary Wharf and 15 miles from Central London, with helicopter transfers taking passengers to and from the heart of the British capital in just six minutes, with limousine transfers taking less than 50 minutes.

The modern airport runway (1,806 meters) allows most aircraft to operate without payload or range restrictions, including non–stop transatlantic flights.

"We are pleased with our arrival in London. Jetex already has a strong presence in Continental Europe with a flagship private jet terminal at Paris Le Bourget, and the new flagship Jetex London is a natural evolution of our operations. Jetex passengers will enjoy a seamless travel experience complemented by the greatest levels of luxury hospitality, unseen before in the market." said Adel Mardini, Founder & CEO of Jetex.

Jetex London will offer a suite of flagship services for passengers and crews traveling through the airport. It is a seamless, intuitive and dedicated route for Jetex customers to begin or end their journey in supreme comfort. The on–site U.K. Border Force and customs control will ensure that passengers and crew enjoy an efficient ground experience, while Jetex will also offer assistance with ground transport, hotel accommodation, catering, concierge services and much more.

"We are very delighted to welcome this new partnership with Jetex, one of the top names in executive aviation, and are looking forward to operating in Biggin Hill together. The airport is already one of the key points for Avia Solutions Group, as our subsidiary JETMS Completions is successfully running aircraft interior and exterior completions there. Thus, the partnership is opening even more opportunities for further business expansion as well as collaboration on future projects. We see great things ahead," said Vygaudas Uackas, Member of the Board of Directors at Avia Solutions Group.

"Jetex is a globally admired brand and we are proud to have the company join our ecosystem of aviation businesses here at London Biggin Hill Airport. We know Jetex will provide an excellent continuity of service and we are looking forward to seeing them thrive," said Robert Walters, Commercial Director, London Biggin Hill Airport.

With natural materials, soft lighting, and floor–to–ceiling windows, Jetex London is designed to feel like a warm, contemporary space. The 1,900 sq.m. private terminal will include several supremely comfortable lounges of understated luxury designed with passenger privacy in mind, a cigar lounge, retail and entertainment areas, fully–equipped boardrooms, shower suites and much more. Crews will appreciate a full range of on–site recreational and flight support facilities.

Jetex London marks the company's first entry into the United Kingdom as it looks forward to growing its operations in the market.

– END –

About Jetex:

An award–winning global leader in executive aviation, Jetex is recognized for delivering flexible, best–in–class trip support solutions to customers worldwide. Jetex provides exceptional private terminals (FBOs), aircraft fueling, ground handling and global trip planning. The company caters to both owners and operators of business jets for corporate, commercial and personal air travel. To find out more about Jetex, visit www.jetex.com and follow us on Instagram, Twitter, Facebook, and LinkedIn.

About Avia Solutions Group:

Leaders in end–to–end capacity solutions for passenger and cargo airlines worldwide. The Group manages over 100 offices and production facilities globally and is significantly backed by the assets of over 7,000 highly skilled aviation professionals, serving more than 2,000 clients throughout Europe, Asia, North America, Australia, and worldwide.

Attachment


GLOBENEWSWIRE (Distribution ID 8546965)

Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics

Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) —

Summary

  • Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistance
  • The company is the first to publicly announce that Its entire supply chain of oral antibiotics "" including its own and supplier manufacturing sites – is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance
  • This achievement demonstrates Centrient Pharmaceuticals' commitment and leadership in the responsible production of antibiotics.

Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral antibiotics product range. This standard covers both Centrient's sites and its suppliers' sites. This achievement positions the company as a frontrunner in the industry with the delivery of responsibly–produced antibiotics, which minimize the possible contribution to antimicrobial resistance.

The PNEC discharge target is the concentration of an antibiotic in water at which there is unlikely to be a risk of adverse environmental effects or of antimicrobial resistance (AMR) developing. These scientific, risk–based targets were developed by the AMR Industry Alliance and cover around 120 active pharmaceutical ingredients (APIs) used in antibiotic manufacturing. Each individual antibiotic has a corresponding PNEC value, published in the AMR Industry Alliance table of Recommended PNECs for Risk Assessments (updated periodically).

High concentrations of antibiotic residues in factory wastewater can create hotspots of resistant bacteria which may lead to AMR. While manufacturing is just one of the contributors to the emergence of AMR in the environment, its impact cannot be overlooked. AMR is a major threat to global public health as well as to the healthcare industry. Many standard medical procedures such as organ transplants, chemotherapy, and surgeries such as caesarean sections become much more dangerous without effective antibiotics to prevent and treat infections. Antibiotics are the cornerstone of our modern healthcare system, and complying with PNEC standards enables manufacturers to ensure supply of these critically important medicines does not contribute to the risk of AMR.

The PNEC values are increasingly being recognized as the standard for antibiotic discharge concentrations in water and are expanding beyond Alliance companies and their supply chains. For example, tenders in the UK and Germany (health insurer AOK) include a specific reference to the PNEC discharge targets. Also, companies assessed externally by organizations such as the Access to Medicine Foundation will have public exposure for their performance on PNECs.

As a strong advocate for sustainable manufacturing, Centrient Pharmaceuticals became a founding board member of the AMR Industry Alliance in 2017, working with partners to raise awareness and deliver solutions to the AMR issue. Since then, the company's own journey to reaching full compliance has included establishing state–of–the–art wastewater treatment facilities at all their sites worldwide and developing tests for measuring antibiotic activity in wastewater streams, leading to a fully clean and PNEC–compliant supply chain.

"We are proud to be the first in our industry to publicly announce PNEC compliance for our oral antibiotics product supply chain.

At Centrient Pharmaceuticals, our commitment to Sustainability is in our DNA "" we ensure that the way in which we produce pharmaceuticals has the lowest environmental impact and does not contribute to AMR. We are proud of our PureActives enzymatic low–carbon technology, ISO 14001 certification of all our sites, and Board positions at the Pharmaceutical Supply Chain Initiative and AMR Industry Alliance.

We will continue to work with customers, suppliers, industry and government decision–makers across the value chain to make the supply and buying of antibiotics sustainable to curb AMR.", says Rex Clements, CEO at Centrient Pharmaceuticals.

Read our whitepaper "Manufacturing sustainable antibiotics for the future' here.

—————————————————————————————————————————————————————————————–


About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next–generation statins, and anti–fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.

We stand proudly at the centre of modern healthcare, as a maker of essential and life–saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2,200 employees work continuously to meet our customers' needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the "Nederlandsche Gist– en Spiritusfabriek', our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rijswijk (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E–Mail: [email protected].

About the AMR Industry Alliance

The AMR Industry Alliance was formed in 2017. With approximately 100 life sciences companies and trade associations, it represents nearly one–third of the volume of sales and the majority of all novel products. Members have committed to report on activities they are undertaking in the areas of research & science, access to antibiotics and appropriate use of these, as well as responsible environmental manufacturing to tackle the rapid spread of antimicrobial resistance. If AMR remains unchecked, the annual death toll could climb from 700,000 each year to 10 million by 2050 and the economic impacts could be on par with those of the 2008 financial crisis. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap for Progress on Combating AMR and measures progress made in the fight against AMR.

Forward–looking statements

This press release may contain forward–looking statements with respect to Centrient Pharmaceuticals' future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.


GLOBENEWSWIRE (Distribution ID 8545387)

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

  • Dante Labs is a Global Leader in Genomics and Precision Medicine
  • Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's flagship product, a highly efficacious and easy to use at–home detection test for colorectal cancer (CRC).

Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next–generation diagnostic tools direct to consumers and healthcare professionals. Inherent to Dante Lab's business model is managing state–of–the–art genomic sequencing laboratories in multiple international regions, and operating a robust e–commerce platform.

"As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it's an absolute pleasure to partner with an industry leader such as Dante Labs," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "Our differentiated commercial plan of partnering with third–party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like–minded companies such as Dante Labs, who share our passion for forward–thinking diagnostic test development and marketing strategies."

The partnership will first launch ColoAlert in Italy and UAE using Dante's various established commercial channels. Samples will initially be processed at Mainz's in–house facility and then Dante will purchase Mainz's CE–IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante's wholly–owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.

"We are excited by the opportunity to align with Mainz and represent ColoAlert in these initial markets," commented Andrea Riposati, Chief Executive Officer of Dante Labs. "Both the product and the Company mirror our mission to develop and market top–tier preventive health solutions and use new channels to make innovative tests available to more patients around the world. With the launch of our enhanced ecommerce platforms for advanced diagnostics, ColoAlert is an amazing product to deliver more personalized medicine."

ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test's initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.

About ColoAlert

ColoAlert detects colorectal cancer (CRC) via a simple–to–administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE–IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company's commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

*Dollinger MM et al. (2018)

About Colorectal Cancer

Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late–stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US–based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.

About Mainz Biomed N.V.

Mainz Biomed develops market–ready molecular genetic diagnostic solutions for life–threatening conditions. The Company's flagship product is ColoAlert, an accurate, non–invasive, and easy–to–use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed's product candidate portfolio includes PancAlert, an early–stage pancreatic cancer screening test based on Real–Time Polymerase Chain Reaction–based (PCR) multiplex detection of molecular–genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

For more information please visit www.mainzbiomed.com

For media enquiries, please contact [email protected]

For investor enquiries, please contact [email protected]

About Dante Labs
Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:

Laura D'Angelo
VP of Investor Relations
[email protected]
+39 0862 191 0671
www.dantelabs.com

Forward–Looking Statements

Certain statements made in this press release are "forward–looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward–looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward–looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward–looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward–looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID–19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward–looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward–looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.


GLOBENEWSWIRE (Distribution ID 8545842)

Global Fishing Watch welcomes partnership with Benin to combat illegal fishing

London, United Kingdom, May 18, 2022 (GLOBE NEWSWIRE) — LONDON, May 19, 2022 – A new partnership agreement between Benin and Global Fishing Watch aims to strengthen monitoring, control and surveillance of fishing activities within the waters of the West African State.

Under the memorandum of understanding, Global Fishing Watch will provide technical support, including fisheries analysis, capacity building and training on its vessel monitoring tools. To track its fishing fleet, Benin is establishing a vessel monitoring system, or VMS, and has formally agreed to share its data via the Global Fishing Watch map""the first African nation to commit to making its fishing fleet publicly visible.

Benin recently hosted in the large port city of Cotonou the first workshop under the new partnership, bringing together participants from Global Fishing Watch and various government agencies to develop actions to combat illegal, unreported and unregulated (IUU) fishing and advance collaboration through open and shared data.

"We are committed to eradicating illegal fishing from our waters and taking all action necessary to secure sustainable fisheries," said the Honorable Gaston Cossi Dossouhoui, Minister for Agriculture, Livestock and Fisheries, Benin. "Through our partnership with Global Fishing Watch, we can strengthen our ability to monitor fishing activity, enforce the law and demonstrate our commitment to transparency in support of a blue economy. We encourage other African States to join us in this initiative to rid our waters of illicit activity."

Captain (Navy) Fernand Maxime Ahoyo, Maritime Prefect of Benin added, "Global Fishing Watch's tools will reinforce Benin's actions to protect its maritime area." Captain Ahoyo also acknowledged support from the non–profit organization, EcoBenin in facilitating engagement between the government of Benin and Global Fishing Watch.

"Greater transparency in fishing activity is an effective and cost–efficient means of driving more compliant behavior at sea. It allows law–abiding fishers to be rewarded, while those with missing information can be investigated and enforcement action more targeted," said Dame Mboup, Global Fishing Watch's program manager for West and Central Africa. "Violations by unauthorized vessels are prevalent off West Africa's coast; Benin is demonstrating leadership in using cutting–edge technology and open data to combat illegal fishing."

Persistent IUU fishing represents a considerable challenge for Benin and other coastal States in the Gulf of Guinea""a vast and diverse region spanning approximately 3,500 miles (5,633 kilometers) of coastline from Senegal to Angola. IUU fishing accounts for nearly 40 percent of all the fish caught in West Africa and threatens the ability of the region's developing countries to maximize the use of their ocean resources.

In addition to the partnership with Benin, Global Fishing Watch has signed letters of intent with Cameroon, Gabon, Guinea, Mauritania and Senegal to strengthen collaboration on governance tools, capacity transfer and analysis. The Regional Fisheries Commission for the Gulf of Guinea and the Sub–regional Fisheries Commission have also expressed their interest in joining Global Fishing Watch's vision for greater fisheries transparency, recognizing that regional cooperation and information sharing is needed to combat IUU fishing.

"West African countries rely on fish as a vital source of protein, income and employment for nearly 7 million people. But this region has seen its fish stocks decline drastically," added Dame Mboup. "Regional collaboration is critical to eliminate IUU fishing and restore fish populations. Global Fishing Watch is excited to support a growing number of West African States working together to share fishing data and harness technology to safeguard their marine resources and promote economic security."

Countries in the Gulf of Guinea recently stepped up the fight against IUU fishing and related crimes. Benin, Cte d'Ivoire, Ghana, Liberia, Nigeria and Togo, through the Fisheries Committee for the West Central Gulf of Guinea (FCWC)""an intergovernmental organization that promotes regional cooperation in fisheries management""launched the Regional Monitoring, Control and Surveillance Center to monitor fishing and related activities in the Gulf of Guinea.

In support of regional efforts to combat IUU fishing, Global Fishing Watch and the international nonprofit, TM–Tracking launched a pilot project with Cte d'Ivoire, Ghana, Kenya, Senegal and the FCWC to provide authorities with satellite tracking data, analysis and training needed to assess a fishing vessel's recent operations and compliance risk. The collaboration will harness a new tool called vessel viewer, which was developed by the two organizations and provides vital information on a vessel's identity, fishing activity, port visits and transshipments to help assess the need for inspection and port access.

With support from the Bloomberg Philanthropies, Moore Foundation, OAK Foundation and Oceans 5, Global Fishing Watch is committed to working with States to publicly share their vessel monitoring data and make its analytical tools and innovative technologies available to help enhance maritime surveillance.

"Achieving sustainable and equitable management of fisheries is critical," said Melissa Wright, Vibrant Oceans Initiative Lead at Bloomberg Philanthropies. "Fisheries support the health and well–being of coastal communities, and Bloomberg Philanthropies is excited for the opportunity to expand the number of organizations that make fishing information available and accessible to governments, civil society and the public. This is an important step in the fight against illegal fishing "" a problem that requires all hands on deck."

###

Global Fishing Watch is an international nonprofit organization dedicated to advancing ocean governance through increased transparency of human activity at sea. By creating and publicly sharing map visualizations, data and analysis tools, we aim to enable scientific research and transform the way our ocean is managed. We believe human activity at sea should be public knowledge in order to safeguard the global ocean for the common good of all.

Attachment


GLOBENEWSWIRE (Distribution ID 8544136)